ALXN - Alexion Pharmaceuticals Stock Price, News & Analysis

$107.60 -0.45 (-0.42 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$108.05
Today's Range$107.07 - $108.55
52-Week Range$96.18 - $149.34
Volume1.80 million shs
Average Volume2.29 million shs
Market Capitalization$24.04 billion
P/E Ratio22
Dividend YieldN/A
Beta1.22

About Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals logoAlexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.


Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALXN
CUSIP01535110

Debt

Debt-to-Equity Ratio0.35%
Current Ratio2.96%
Quick Ratio2.51%

Price-To-Earnings

Trailing P/E Ratio22
Forward P/E Ratio22.37
P/E Growth1.17

Sales & Book Value

Annual Sales$3.08 billion
Price / Sales7.79
Cash Flow$6.00 per share
Price / Cash17.92
Book Value$40.03 per share
Price / Book2.69

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS$2.24
Net Income$399 million
Net Margins14.57%
Return on Equity12.55%
Return on Assets8.25%

Miscellaneous

Employees3,121
Outstanding Shares223,410,000

Frequently Asked Questions for Alexion Pharmaceuticals (NASDAQ:ALXN)

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How will Alexion Pharmaceuticals' stock buyback program work?

Alexion Pharmaceuticals announced that its board has initiated a stock repurchase program on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 3.4% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board of directors believes its stock is undervalued.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced its quarterly earnings results on Thursday, October, 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating analysts' consensus estimates of $1.32 by $0.12. The biopharmaceutical company earned $859 million during the quarter, compared to analysts' expectations of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. Alexion Pharmaceuticals's revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.23 earnings per share. View Alexion Pharmaceuticals' Earnings History.

When will Alexion Pharmaceuticals make its next earnings announcement?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for Alexion Pharmaceuticals.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals updated its FY17 earnings guidance on Thursday, October, 26th. The company provided earnings per share (EPS) guidance of $5.50-5.65 for the period, compared to the Thomson Reuters consensus estimate of $5.60. The company issued revenue guidance of $3.475-3.525 billion, compared to the consensus revenue estimate of $3.53 billion.

Where is Alexion Pharmaceuticals' stock going? Where will Alexion Pharmaceuticals' stock price be in 2017?

22 analysts have issued twelve-month target prices for Alexion Pharmaceuticals' stock. Their forecasts range from $120.00 to $182.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $155.48 in the next year. View Analyst Ratings for Alexion Pharmaceuticals.

What are Wall Street analysts saying about Alexion Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Alexion topped earnings estimates but missed on revenues in the third quarter. The increase in earnings guidance was also positive. Alexion’s blockbuster drug, Soliris, continues to perform well and the FDA approval of the drug for generalized myasthenia gravis will further boost sales. Among new products, while Strensiq is gaining momentum, the company redefined its strategy for Kanuma which earlier lagged expectations. In order to focus better in core areas, Alexion has de-prioritized a few clinical programs and terminated its partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma. However, the company relies heavily on Soliris for growth and sales of Soliris will be impacted by ramp of ALXN1210 trials while pricing will impact Strensiq revenues going forward.Shares of the company have underperformed the industry in the last six months." (11/1/2017)
  • 2. J P Morgan Chase & Co analysts commented, "Additionally, post a series of physician calls in the space, while competitor complement players will have updates in the next 6-18 months, we believe the '1210 profile is already clinically compelling and the burden is on competitors to produce meaningful data," (9/5/2017)
  • 3. Morgan Stanley analysts commented, "re-prioritize the strategic direction" of the company. Furthermore, the second-quarter strategic review serves as a "turning point" for investor sentiment."While we understand investor unease that another 'shoe could drop' on this story, we see the risk/reward as compelling and believe new management is making progress right sizing the company and refocusing its efforts," the analyst wrote.2. Underappreciated StoryHarrison also believes Alexion's stock is pricing "little-to-no value" for the ALXN1210 life-cycle extension strategy. Meanwhile, investors are under-appreciating the antibody but the sentiment could turn move positive with potential gMG approval and the release of pivotal data.Harrison also believes Alexion's core asset value is "not impaired." Also, the analyst suggested that the underlying patient need and use of Solaris is "sound" and the company's strategy to protect Solaris through new IP and ALXN1210 is "very defensible with clarity on this strategy coming in less than 12 months." (5/25/2017)
  • 4. Barclays PLC analysts commented, "provides support to the patient association in Brazil in the form of unrestricted educational grants and in accordance with local laws and regulations and industry code." In addition, the spokesperson confirmed that Alexion has not been charged with any criminal or civil misconduct.Investors Shrug Barclays' CallShortly after reports of Alexion's raid on Monday, analysts at Barclays offered a quick take on how investors should react.Barclays' Geoff Meacham suggested that while the headline report looks "onerous," the report shouldn't be viewed as a major fundamental concern. The analyst cited "good Soliris growth" (5/9/2017)
  • 5. Cowen Inc analysts commented, "We recently hosted investor meetings with CEO Ludwig Hantson, CFO Dave." (4/28/2017)

Who are some of Alexion Pharmaceuticals' key competitors?

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the folowing people:

  • David R. Brennan, Chairman of the Board (Age 63)
  • Ludwig N. Hantson Ph.D., Chief Executive Officer, Director (Age 54)
  • Paul J. Clancy, Chief Financial Officer (Age 55)
  • John B. Moriarty J.D., Executive Vice President, General Counsel (Age 49)
  • Martin Mackay Ph.D., Executive Vice President, Global Head - Research and Development (Age 60)
  • Julie O'Neill, Executive Vice President - Global Operations (Age 50)
  • Edward Miller J.D., Senior Vice President, Global Chief Compliance Officer (Age 52)
  • Heidi L. Wagner J.D., Senior Vice President - Global Governmental Affairs (Age 52)
  • Brian Goff, Chief Commercial Officer (Age 48)
  • Paul A. Friedman M.D., Director (Age 74)

Who owns Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ameriprise Financial Inc. (2.86%), Jennison Associates LLC (2.39%), Orbimed Advisors LLC (1.63%), Bank of New York Mellon Corp (1.43%), Wells Fargo & Company MN (0.70%) and Temasek Holdings Private Ltd (0.67%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Ludwig Hantson, Martin Mackay, Saqib Islam and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Who sold Alexion Pharmaceuticals stock? Who is selling Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Third Point LLC, Orbimed Advisors LLC, Bank of New York Mellon Corp, Highbridge Capital Management LLC, Janus Henderson Group PLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp and OxFORD Asset Management LLP. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Alvin S Parven, Ann M Veneman, Carsten Thiel, Clare Carmichael, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill and Leonard Bell. View Insider Buying and Selling for Alexion Pharmaceuticals.

Who bought Alexion Pharmaceuticals stock? Who is buying Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Assenagon Asset Management S.A., Alkeon Capital Management LLC, Wells Fargo & Company MN, Pictet Asset Management Ltd., DSM Capital Partners LLC, Ameriprise Financial Inc. and American Century Companies Inc.. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

How do I buy Alexion Pharmaceuticals stock?

Shares of Alexion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of Alexion Pharmaceuticals stock can currently be purchased for approximately $107.60.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $24.04 billion and generates $3.08 billion in revenue each year. The biopharmaceutical company earns $399 million in net income (profit) each year or $2.24 on an earnings per share basis. Alexion Pharmaceuticals employs 3,121 workers across the globe.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 100 COLLEGE STREET, NEW HAVEN CT, 06510. The biopharmaceutical company can be reached via phone at 475-230-2596.


MarketBeat Community Rating for Alexion Pharmaceuticals (ALXN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  811 (Vote Outperform)
Underperform Votes:  443 (Vote Underperform)
Total Votes:  1,254
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Alexion Pharmaceuticals (NASDAQ:ALXN)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.902.78
Ratings Breakdown: 0 Sell Ratings
6 Hold Ratings
21 Buy Ratings
2 Strong Buy Ratings
0 Sell Ratings
6 Hold Ratings
21 Buy Ratings
2 Strong Buy Ratings
0 Sell Ratings
6 Hold Ratings
20 Buy Ratings
3 Strong Buy Ratings
0 Sell Ratings
7 Hold Ratings
19 Buy Ratings
1 Strong Buy Ratings
Consensus Price Target: $156.63$157.17$156.13$165.01
Price Target Upside: 38.06% upside16.25% upside17.04% upside63.25% upside

Consensus Price Target History for Alexion Pharmaceuticals (NASDAQ:ALXN)

Price Target History for Alexion Pharmaceuticals (NASDAQ:ALXN)

Analysts' Ratings History for Alexion Pharmaceuticals (NASDAQ:ALXN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/24/2017Royal Bank Of CanadaBoost Price Target$166.00N/AView Rating Details
10/24/2017Stifel NicolausLower Price TargetBuy$165.00 -> $159.00N/AView Rating Details
10/23/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$170.00N/AView Rating Details
9/25/2017Leerink SwannReiterated RatingBuy$182.00LowView Rating Details
9/13/2017Deutsche Bank AGReiterated RatingBuy -> Buy$153.00 -> $158.00LowView Rating Details
9/13/2017SunTrust Banks, Inc.Reiterated RatingBuy$170.00 -> $180.00MediumView Rating Details
9/13/2017BMO Capital MarketsReiterated RatingOutperform$168.00 -> $173.00MediumView Rating Details
9/5/2017J P Morgan Chase & CoUpgradeNeutral -> Overweight$163.00 -> $175.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$137.00MediumView Rating Details
7/28/2017Oppenheimer Holdings, Inc.UpgradeMarket Perform -> Outperform$175.00HighView Rating Details
7/28/2017Morgan StanleyReiterated RatingOverweight$141.00 -> $153.00HighView Rating Details
7/3/2017Cowen IncReiterated RatingOutperform$122.00HighView Rating Details
6/26/2017Robert W. BairdReiterated RatingNeutral$145.00MediumView Rating Details
6/14/2017Credit Suisse GroupSet Price TargetBuy$164.00MediumView Rating Details
6/9/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$142.00LowView Rating Details
6/8/2017Jefferies Group LLCSet Price TargetHold$120.00MediumView Rating Details
5/24/2017Barclays PLCReiterated RatingOverweight$155.00HighView Rating Details
5/9/2017Raymond James Financial, Inc.Reiterated RatingStrong-Buy$176.00LowView Rating Details
3/30/2017InstinetReiterated RatingBuy$148.00LowView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/13/2016WedbushReiterated RatingNeutral$135.00N/AView Rating Details
11/30/2016FBR & CoReiterated RatingMarket Perform$130.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$221.00N/AView Rating Details
9/20/2016Citigroup Inc.Boost Price TargetBuy$154.00 -> $155.00N/AView Rating Details
6/6/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
1/7/2016BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Alexion Pharmaceuticals (NASDAQ:ALXN)

Earnings by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Earnings History by Quarter for Alexion Pharmaceuticals (NASDAQ ALXN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018$1.27N/AView Earnings Details
10/26/2017Q3 2017$1.32$1.44$864.34 million$859.00 millionViewN/AView Earnings Details
7/27/2017Q2 2017$1.08$1.56$846.15 million$912.00 millionViewN/AView Earnings Details
4/27/2017Q1 2017$1.05$1.38$826.63 million$870.00 millionViewN/AView Earnings Details
2/16/2017Q416$1.25$1.26$840.69 million$831.00 millionViewN/AView Earnings Details
10/27/2016Q316$1.04$1.23$787.07 million$799.00 millionViewListenView Earnings Details
7/28/2016Q216$0.91$1.13$743.18 million$753.00 millionViewListenView Earnings Details
4/28/2016Q116$1.13$1.11$710.98 million$701.00 millionViewListenView Earnings Details
2/3/2016Q415$1.10$1.13$703.42 million$701.00 millionViewN/AView Earnings Details
10/29/2015Q315$1.01$1.16$668.33 million$666.60 millionViewListenView Earnings Details
7/30/2015Q215$1.31$1.44$628.03 million$636.00 millionViewListenView Earnings Details
4/23/2015Q115$1.18$1.28$594.40 million$600.30 millionViewN/AView Earnings Details
1/29/2015Q414$1.17$1.13$589.85 million$599.00 millionViewListenView Earnings Details
10/23/2014Q314$1.05$1.27$541.93 million$555.10 millionViewListenView Earnings Details
7/24/2014Q214$0.99$0.99$509.54 million$512.50 millionViewListenView Earnings Details
4/24/2014Q114$1.26$1.53$560.22 million$566.60 millionViewListenView Earnings Details
1/30/2014Q413$0.83$0.87$430.08 million$441.90 millionViewListenView Earnings Details
10/24/2013Q313$0.79$0.83$395.10 million$400.40 millionViewListenView Earnings Details
7/25/2013Q2 2013$0.68$0.73$364.80 million$370.10 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.61$0.65$336.56 million$338.90 millionViewListenView Earnings Details
2/14/2013Q4 2012$0.52$0.60$316.49 million$320.50 millionViewListenView Earnings Details
10/24/2012$0.47$0.60ViewN/AView Earnings Details
7/25/2012$0.36$0.47ViewN/AView Earnings Details
4/24/2012$0.38$0.45ViewN/AView Earnings Details
2/9/2012$0.33$0.41ViewN/AView Earnings Details
10/20/2011$0.28$0.37ViewN/AView Earnings Details
7/21/2011$0.26$0.29ViewN/AView Earnings Details
4/21/2011$0.51$0.59ViewN/AView Earnings Details
2/10/2011$0.50$0.51ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alexion Pharmaceuticals (NASDAQ:ALXN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$1.04$1.04$1.04
Q2 20171$1.15$1.15$1.15
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alexion Pharmaceuticals (NASDAQ:ALXN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alexion Pharmaceuticals (NASDAQ ALXN)

Insider Ownership Percentage: 4.35%
Institutional Ownership Percentage: 95.80%
Insider Trades by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)
Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Insider Trades by Quarter for Alexion Pharmaceuticals (NASDAQ ALXN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Heidi L WagnerSVPSell120$140.00$16,800.00View SEC Filing  
9/5/2017Ann M VenemanDirectorSell835$145.81$121,751.35View SEC Filing  
9/5/2017Julie O'neillEVPSell4,375$145.44$636,300.00View SEC Filing  
8/28/2017Julie O'neillEVPSell11,160$140.00$1,562,400.00View SEC Filing  
7/31/2017Ann M VenemanDirectorSell700$137.74$96,418.00View SEC Filing  
6/15/2017Bros. Advisors Lp BakerDirectorBuy660,779$117.33$77,529,200.07View SEC Filing  
6/14/2017Bros. Advisors Lp BakerDirectorBuy1,348,955$116.32$156,910,445.60View SEC Filing  
6/14/2017Ludwig HantsonCEOBuy10,000$116.72$1,167,200.00View SEC Filing  
3/1/2017Clare CarmichaelEVPSell2,179$131.66$286,887.14View SEC Filing  
3/1/2017Heidi L WagnerSVPSell994$131.65$130,860.10View SEC Filing  
3/1/2017Leonard BellDirectorSell3,978$131.96$524,936.88View SEC Filing  
2/28/2017Carsten ThielEVPSell125$74.52$9,315.00View SEC Filing  
2/28/2017Edward MillerSVPSell590$131.48$77,573.20View SEC Filing  
2/28/2017Leonard BellDirectorSell2,738$131.71$360,621.98View SEC Filing  
2/27/2017Edward MillerSVPSell260$131.20$34,112.00View SEC Filing  
2/27/2017John B MoriartyEVPSell612$131.20$80,294.40View SEC Filing  
2/9/2017John B MoriartyEVPSell167$126.84$21,182.28View SEC Filing  
2/9/2017Leonard BellDirectorSell246$126.84$31,202.64View SEC Filing  
2/7/2017Heidi L WagnerSVPSell1,932$125.97$243,374.04View SEC Filing  
2/7/2017John B MoriartyEVPSell3,538$125.79$445,045.02View SEC Filing  
2/7/2017Leonard BellDirectorSell8,725$125.97$1,099,088.25View SEC Filing  
1/10/2017Leonard BellDirectorSell100$144.99$14,499.00View SEC Filing  
1/9/2017Leonard BellDirectorSell40,065$138.48$5,548,201.20View SEC Filing  
1/5/2017Alvin S ParvenDirectorSell22,659$138.35$3,134,872.65View SEC Filing  
12/12/2016John B MoriartyEVPSell1,044$118.61$123,828.84View SEC Filing  
12/9/2016Carsten ThielEVPSell2,308$130.00$300,040.00View SEC Filing  
11/14/2016Heidi L WagnerSVPSell59$115.10$6,790.90View SEC Filing  
11/4/2016Leonard BellDirectorSell37,317$140.38$5,238,560.46View SEC Filing  
10/31/2016Leonard BellDirectorSell1,300$135.28$175,864.00View SEC Filing  
10/14/2016Carsten ThielEVPSell4,584$120.28$551,363.52View SEC Filing  
10/3/2016Carsten ThielEVPSell29$122.41$3,549.89View SEC Filing  
10/3/2016Heidi L WagnerSVPSell120$122.41$14,689.20View SEC Filing  
9/13/2016Carsten ThielEVPSell3,225$128.67$414,960.75View SEC Filing  
9/9/2016Edward MillerSVPSell367$128.32$47,093.44View SEC Filing  
9/6/2016Carsten ThielEVPSell1,000$125.94$125,940.00View SEC Filing  
9/2/2016Julie O'neillEVPSell650$126.29$82,088.50View SEC Filing  
8/30/2016Clare CarmichaelEVPSell1,000$127.76$127,760.00View SEC Filing  
8/22/2016Alvin S ParvenDirectorSell15,000$136.53$2,047,950.00View SEC Filing  
8/15/2016Alvin S ParvenDirectorSell700$135.51$94,857.00View SEC Filing  
8/8/2016Clare CarmichaelEVPSell165$137.14$22,628.10View SEC Filing  
8/8/2016David HallalCEOSell332$137.14$45,530.48View SEC Filing  
8/8/2016Heidi L WagnerSVPSell222$137.14$30,445.08View SEC Filing  
8/8/2016Leonard BellDirectorSell1,010$137.14$138,511.40View SEC Filing  
8/8/2016Vikas SinhaCFOSell277$137.14$37,987.78View SEC Filing  
6/13/2016John B MoriartyEVPSell918$135.72$124,590.96View SEC Filing  
5/16/2016Martin MackayEVPSell4,097$139.20$570,302.40View SEC Filing  
5/13/2016Heidi L WagnerSVPSell53$138.65$7,348.45View SEC Filing  
4/1/2016David HallalCEOSell1,414$135.88$192,134.32View SEC Filing  
2/29/2016Clare CarmichaelEVPSell1,312$138.91$182,249.92View SEC Filing  
2/29/2016David HallalCEOSell2,014$138.93$279,805.02View SEC Filing  
2/29/2016Edward MillerSVPSell329$138.91$45,701.39View SEC Filing  
2/29/2016Leonard BellDirectorSell3,995$138.92$554,985.40View SEC Filing  
2/29/2016Vikas SinhaCFOSell1,122$138.91$155,857.02View SEC Filing  
2/8/2016David HallalCEOSell11,297$140.50$1,587,228.50View SEC Filing  
2/8/2016Heidi L. WagnerSVPSell2,108$140.93$297,080.44View SEC Filing  
2/8/2016Julie O'neillEVPSell2,858$141.83$405,350.14View SEC Filing  
2/8/2016Leonard BellDirectorSell15,872$139.58$2,215,413.76View SEC Filing  
2/8/2016Vikas SinhaCFOSell6,547$140.04$916,841.88View SEC Filing  
2/5/2016Edward MillerSVPSell1,051$143.02$150,314.02View SEC Filing  
12/29/2015Leonard BellDirectorSell35,000$190.66$6,673,100.00View SEC Filing  
12/17/2015Leonard BellDirectorSell70,000$187.69$13,138,300.00View SEC Filing  
12/11/2015Ann M VenemanDirectorSell895$187.48$167,794.60View SEC Filing  
12/11/2015John B. MoriartyEVPSell943$182.73$172,314.39View SEC Filing  
12/8/2015Leonard BellDirectorSell70,000$188.20$13,174,000.00View SEC Filing  
12/8/2015Saqib IslamEVPSell950$190.00$180,500.00View SEC Filing  
11/25/2015Leonard BellDirectorSell35,000$181.89$6,366,150.00View SEC Filing  
10/26/2015Saqib IslamEVPSell1,558$168.44$262,429.52View SEC Filing  
9/9/2015Leonard BellDirectorSell1,050$180.10$189,105.00View SEC Filing  
6/18/2015Leonard BellDirectorSell27,835$179.63$5,000,001.05View SEC Filing  
3/19/2015Leonard BellCEOSell15,952$188.07$3,000,092.64View SEC Filing  
3/2/2015Julie O'neillEVPSell11,665$101.49$1,183,880.85View SEC Filing  
3/2/2015Leonard BellCEOSell1,230$180.34$221,818.20View SEC Filing  
2/10/2015Clare CarmichaelEVPSell1,490$171.15$255,013.50View SEC Filing  
2/10/2015David HallalCOOSell1,980$171.15$338,877.00View SEC Filing  
2/10/2015Leonard BellCEOSell5,740$171.15$982,401.00View SEC Filing  
2/10/2015Vikas SinhaCFOSell1,985$171.15$339,732.75View SEC Filing  
2/9/2015Clare CarmichaelEVPSell1,665$173.75$289,293.75View SEC Filing  
2/9/2015David HallalCOOSell2,920$173.93$507,875.60View SEC Filing  
2/9/2015Leonard BellCEOSell8,660$173.98$1,506,666.80View SEC Filing  
2/9/2015Vikas SinhaCFOSell2,703$174.18$470,808.54View SEC Filing  
2/4/2015David HallalCOOSell1,373$174.18$239,149.14View SEC Filing  
2/4/2015Leonard BellCEOSell5,223$174.29$910,316.67View SEC Filing  
2/4/2015Vikas SinhaCFOSell1,571$174.19$273,652.49View SEC Filing  
12/18/2014David HallalCOOSell5,494$182.03$1,000,072.82View SEC Filing  
12/18/2014Leonard BellCEOSell30,415$179.73$5,466,487.95View SEC Filing  
12/18/2014Vikas SinhaCFOSell5,493$182.08$1,000,165.44View SEC Filing  
12/9/2014Leonard BellCEOSell133,320$198.26$26,432,023.20View SEC Filing  
12/4/2014Clare CarmichaelSVPSell10,000$196.25$1,962,500.00View SEC Filing  
12/4/2014William R KellerDirectorSell5,000$196.25$981,250.00View SEC Filing  
12/3/2014Vikas SinhaCFOSell75,000$198.96$14,922,000.00View SEC Filing  
11/3/2014David HallalCOOSell30,000$190.01$5,700,300.00View SEC Filing  
11/3/2014Martin MackayEVPSell9,375$191.52$1,795,500.00View SEC Filing  
11/3/2014Saqib IslamSVPSell28,125$190.50$5,357,812.50View SEC Filing  
11/3/2014Vikas SinhaCFOSell49,307$192.63$9,498,007.41View SEC Filing  
10/27/2014John B MoriartySVPSell10,000$189.49$1,894,900.00View SEC Filing  
10/27/2014Stephen P SquintoEVPSell5,910$188.58$1,114,507.80View SEC Filing  
10/6/2014John B MoriartySVPSell10,000$179.00$1,790,000.00View SEC Filing  
10/3/2014Stephen P SquintoEVPSell10,025$172.41$1,728,410.25View SEC Filing  
9/26/2014Leonard BellCEOSell60,000$165.12$9,907,200.00View SEC Filing  
9/24/2014Stephen P SquintoEVPSell76$159.50$12,122.00View SEC Filing  
9/18/2014Leonard BellCEOSell44,435$160.60$7,136,261.00View SEC Filing  
9/10/2014Leonard BellCEOSell12,199$165.38$2,017,470.62View SEC Filing  
9/8/2014Leonard BellCEOSell197,801$165.32$32,700,461.32View SEC Filing  
8/27/2014Leonard BellCEOSell5,912$169.17$1,000,133.04View SEC Filing  
8/25/2014Andreas RummeltDirectorSell5,052$170.53$861,517.56View SEC Filing  
8/15/2014Leonard BellCEOSell70,000$167.99$11,759,300.00View SEC Filing  
8/13/2014Leonard BellCEOSell105,000$160.71$16,874,550.00View SEC Filing  
8/12/2014Leonard BellCEOSell80,458$160.16$12,886,153.28View SEC Filing  
8/4/2014David HallalEVPSell1,349$158.00$213,142.00View SEC Filing  
8/4/2014Leonard BellCEOSell5,145$157.88$812,292.60View SEC Filing  
8/4/2014Vikas SinhaCFOSell1,525$157.82$240,675.50View SEC Filing  
7/30/2014Leonard BellCEOSell127,289$162.93$20,739,196.77View SEC Filing  
7/29/2014Leonard BellCEOSell1,200$164.93$197,916.00View SEC Filing  
7/28/2014Leonard BellCEOSell105,600$162.38$17,147,328.00View SEC Filing  
6/20/2014Leonard BellCEOSell90,280$163.60$14,769,808.00View SEC Filing  
6/12/2014Martin MackayEVPSell25,000$166.42$4,160,500.00View SEC Filing  
6/5/2014William R KellerDirectorSell3,425$170.00$582,250.00View SEC Filing  
5/27/2014Leonard BellCEOSell70,000$166.16$11,631,200.00View SEC Filing  
5/20/2014Leonard BellCEOSell70,000$155.96$10,917,200.00View SEC Filing  
5/14/2014Martin MackayEVPSell3,574$160.85$574,877.90View SEC Filing  
5/13/2014Alvin ParvenDirectorSell12,276$160.78$1,973,735.28View SEC Filing  
4/29/2014Leonard BellCEOSell70,000$156.20$10,934,000.00View SEC Filing  
2/10/2014Stephen SquintoEVPSell7,055$158.04$1,114,972.20View SEC Filing  
2/7/2014David HallalEVPSell1,620$155.57$252,023.40View SEC Filing  
2/7/2014Frank WrightSVPSell1,098$155.57$170,815.86View SEC Filing  
2/7/2014Joseph MadriDirectorSell30,000$159.00$4,770,000.00View SEC Filing  
2/7/2014Leonard BellCEOSell4,620$155.56$718,687.20View SEC Filing  
2/4/2014Leonard BellCEOSell11,790$154.50$1,821,555.00View SEC Filing  
2/4/2014Stephen SquintoEVPSell36,989$155.12$5,737,733.68View SEC Filing  
2/4/2014Vikas SinhaCFOSell3,552$154.47$548,677.44View SEC Filing  
1/29/2014Leonard BellCEOSell2,660$133.81$355,934.60View SEC Filing  
1/29/2014Stephen SquintoEVPSell1,118$133.31$149,040.58View SEC Filing  
1/22/2014Leonard BellCEOSell156,436$140.80$22,026,188.80View SEC Filing  
1/10/2014Leonard BellCEOSell19,155$134.98$2,585,541.90View SEC Filing  
12/19/2013Leonard BellCEOSell175,000$126.38$22,116,500.00View SEC Filing  
10/28/2013Stephen P SquintoEVPSell41,037$124.06$5,091,050.22View SEC Filing  
10/28/2013Vikas SinhaCFOSell50,000$122.97$6,148,500.00View SEC Filing  
9/16/2013Joseph MadriDirectorSell30,000$115.00$3,450,000.00View SEC Filing  
9/16/2013Leonard BellCEOSell3,500$115.00$402,500.00View SEC Filing  
9/13/2013Stephen SquintoEVPSell1,000$114.37$114,370.00View SEC Filing  
9/4/2013Leonard BellCEOSell1,850$110.07$203,629.50View SEC Filing  
9/3/2013Leonard BellCEOSell33,150$110.19$3,652,798.50View SEC Filing  
8/30/2013Clare CarmichaelSVPSell1,237$107.58$133,076.46View SEC Filing  
8/16/2013Leonard BellCEOSell140,000$106.08$14,851,200.00View SEC Filing  
8/5/2013Leonard BellCEOSell2,919$116.87$341,143.53View SEC Filing  
8/2/2013Stephen P SquintoEVPSell14,125$115.33$1,629,036.25View SEC Filing  
7/30/2013Leonard BellCEOSell212,737$114.62$24,383,914.94View SEC Filing  
7/30/2013Stephen P SquintoEVPSell1,120$110.86$124,163.20View SEC Filing  
7/12/2013David HallalEVPSell50,000$120.00$6,000,000.00View SEC Filing  
7/1/2013Stephen P SquintoEVPSell44,125$94.97$4,190,551.25View SEC Filing  
5/22/2013R Douglas NorbyDirectorSell40,000$102.77$4,110,800.00View SEC Filing  
5/20/2013William R KellerDirectorSell9,770$103.00$1,006,310.00View SEC Filing  
5/14/2013Leonard BellCEOSell31,113$105.74$3,289,888.62View SEC Filing  
5/13/2013Leonard BellCEOSell41,220$100.85$4,157,037.00View SEC Filing  
4/10/2013Leonard BellCEOSell26,700$100.24$2,676,408.00View SEC Filing  
2/4/2013Leonard BellCEOSell11,880$96.27$1,143,687.60View SEC Filing  
2/4/2013Stephen P SquintoEVPSell2,572$95.68$246,088.96View SEC Filing  
2/4/2013Vikas SinhaCFOSell3,483$95.81$333,706.23View SEC Filing  
1/15/2013Leonard BellCEOSell35,000$98.58$3,450,300.00View SEC Filing  
10/31/2012Patrice CoissacSVPSell84,764$91.16$7,727,086.24View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Alexion Pharmaceuticals (NASDAQ ALXN)

Source:
DateHeadline
Has Alexion Pharmaceuticals Inc (ALXN) Improved Earnings Growth In Recent Times?Has Alexion Pharmaceuticals Inc (ALXN) Improved Earnings Growth In Recent Times?
finance.yahoo.com - November 24 at 11:47 AM
$876.61 Million in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter$876.61 Million in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter
www.americanbankingnews.com - November 24 at 2:34 AM
Stock Traders Buy Large Volume of Alexion Pharmaceuticals Put Options (ALXN)Stock Traders Buy Large Volume of Alexion Pharmaceuticals Put Options (ALXN)
www.americanbankingnews.com - November 24 at 1:26 AM
Zacks: Brokerages Anticipate Alexion Pharmaceuticals, Inc. (ALXN) Will Announce Earnings of $1.28 Per ShareZacks: Brokerages Anticipate Alexion Pharmaceuticals, Inc. (ALXN) Will Announce Earnings of $1.28 Per Share
www.americanbankingnews.com - November 22 at 11:08 PM
Alexion Pharmaceuticals, Inc. (ALXN) Given Consensus Recommendation of "Buy" by AnalystsAlexion Pharmaceuticals, Inc. (ALXN) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 21 at 4:18 AM
Alexion Pharma - Underperformance Does Not Equal Opportunity - Seeking AlphaAlexion Pharma - Underperformance Does Not Equal Opportunity - Seeking Alpha
seekingalpha.com - November 21 at 3:13 AM
ETFs with exposure to Alexion Pharmaceuticals, Inc. : November 13, 2017ETFs with exposure to Alexion Pharmaceuticals, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 2:44 AM
Alexion Suffers Quantitative Downgrade, Bearish ChartsAlexion Suffers Quantitative Downgrade, Bearish Charts
finance.yahoo.com - November 14 at 2:44 AM
Alexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of ServiceAlexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of Service
finance.yahoo.com - November 9 at 4:53 PM
Alexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of ServiceAlexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of Service
finance.yahoo.com - November 9 at 4:53 PM
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) Names Francois Nader to Board of Directors - StreetInsider.comAlexion Pharmaceuticals, Inc. (NASDAQ: ALXN) Names Francois Nader to Board of Directors - StreetInsider.com
www.streetinsider.com - November 8 at 8:44 PM
Alexion Appoints Francois Nader, M.D. to its Board of DirectorsAlexion Appoints Francois Nader, M.D. to its Board of Directors
finance.yahoo.com - November 8 at 8:44 PM
The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in OctoberThe Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October
finance.yahoo.com - November 7 at 5:28 PM
Alexion Pharma (ALXN) Receives New Japanese Patent for Soliris - StreetInsider.comAlexion Pharma (ALXN) Receives New Japanese Patent for Soliris - StreetInsider.com
www.streetinsider.com - November 7 at 3:09 AM
Weak Sales Growth Drop Alexion Pharmaceuticals (ALXN) to SellWeak Sales Growth Drop Alexion Pharmaceuticals (ALXN) to Sell
investorplace.com - November 6 at 8:43 PM
Alexion Granted Additional Patent For Soliris In Japan - Quick FactsAlexion Granted Additional Patent For Soliris In Japan - Quick Facts
www.rttnews.com - November 6 at 4:32 PM
Alexion nabs new patent in Japan covering SolirisAlexion nabs new patent in Japan covering Soliris
seekingalpha.com - November 6 at 4:32 PM
Alexion Pharma (ALXN) Receives New Japanese Patent for SolirisAlexion Pharma (ALXN) Receives New Japanese Patent for Soliris
www.streetinsider.com - November 6 at 4:32 PM
Alexion Receives New Japanese Patent for Soliris® (eculizumab), Extending Patent Protection Into 2027 and Strengthening Global Patent PortfolioAlexion Receives New Japanese Patent for Soliris® (eculizumab), Extending Patent Protection Into 2027 and Strengthening Global Patent Portfolio
finance.yahoo.com - November 6 at 4:32 PM
Zacks: Brokerages Expect Alexion Pharmaceuticals, Inc. (ALXN) Will Post Quarterly Sales of $876.61 MillionZacks: Brokerages Expect Alexion Pharmaceuticals, Inc. (ALXN) Will Post Quarterly Sales of $876.61 Million
www.americanbankingnews.com - November 5 at 4:08 AM
Alexion Pharma (ALXN) Announces New Interim Survival Data on LAL-D Treated with Kanuma (sebelipase alfa) - StreetInsider.comAlexion Pharma (ALXN) Announces New Interim Survival Data on LAL-D Treated with Kanuma (sebelipase alfa) - StreetInsider.com
www.streetinsider.com - November 3 at 3:48 PM
Alexion Pharma (ALXN) Announces New Interim Survival Data on LAL-D Treated with Kanuma (sebelipase alfa)Alexion Pharma (ALXN) Announces New Interim Survival Data on LAL-D Treated with Kanuma (sebelipase alfa)
www.streetinsider.com - November 3 at 9:40 AM
New Interim Data Presented at NASPGHAN 2017 Meeting Show Survival Beyond 1 Year of Age in Infants with LAL-D Treated with Kanuma® (sebelipase alfa)New Interim Data Presented at NASPGHAN 2017 Meeting Show Survival Beyond 1 Year of Age in Infants with LAL-D Treated with Kanuma® (sebelipase alfa)
finance.yahoo.com - November 3 at 9:40 AM
ETFs with exposure to Alexion Pharmaceuticals, Inc. : November 2, 2017ETFs with exposure to Alexion Pharmaceuticals, Inc. : November 2, 2017
finance.yahoo.com - November 2 at 4:10 PM
New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) MeetingNew Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting
finance.yahoo.com - November 1 at 4:17 PM
Alexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017Alexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017
finance.yahoo.com - November 1 at 4:17 PM
Featured Company News - Epizyme Presented Data from Phase-1 Trial of Tazemetostat In Children with Relapsed/Refractory INI1-Negative Solid TumorsFeatured Company News - Epizyme Presented Data from Phase-1 Trial of Tazemetostat In Children with Relapsed/Refractory INI1-Negative Solid Tumors
finance.yahoo.com - October 31 at 4:59 PM
Alexion to Present at the 26th Annual Credit Suisse Healthcare ConferenceAlexion to Present at the 26th Annual Credit Suisse Healthcare Conference
finance.yahoo.com - October 30 at 4:38 PM
Alexion Pharmaceuticals Inc. Profit Advances 17% In Q3Alexion Pharmaceuticals Inc. Profit Advances 17% In Q3
www.rttnews.com - October 27 at 6:00 PM
Alexion Pharmaceuticals, Inc. (ALXN) Given Average Rating of "Buy" by BrokeragesAlexion Pharmaceuticals, Inc. (ALXN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 27 at 3:50 AM
Alexion Pharmaceuticals Inc. Profit Advances 17% In Q3 - NasdaqAlexion Pharmaceuticals Inc. Profit Advances 17% In Q3 - Nasdaq
www.nasdaq.com - October 27 at 1:51 AM
Edited Transcript of ALXN earnings conference call or presentation 26-Oct-17 2:00pm GMTEdited Transcript of ALXN earnings conference call or presentation 26-Oct-17 2:00pm GMT
finance.yahoo.com - October 27 at 1:51 AM
Oversold Conditions For Alexion Pharmaceuticals (ALXN)Oversold Conditions For Alexion Pharmaceuticals (ALXN)
www.nasdaq.com - October 26 at 8:49 PM
Alexion Pharmaceuticals (ALXN) Q3 2017 Results - Earnings Call TranscriptAlexion Pharmaceuticals (ALXN) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - October 26 at 8:49 PM
Alexion (ALXN) Tops Q3 Earnings, Lags Sales, 2017 View UpAlexion (ALXN) Tops Q3 Earnings, Lags Sales, 2017 View Up
www.nasdaq.com - October 26 at 3:49 PM
Alexion Reports Third Quarter 2017 ResultsAlexion Reports Third Quarter 2017 Results
finance.yahoo.com - October 26 at 3:49 PM
Alexion beats 3Q profit forecastsAlexion beats 3Q profit forecasts
finance.yahoo.com - October 26 at 3:49 PM
Alexion Pharmaceuticals, Inc. to Host Earnings CallAlexion Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - October 26 at 3:49 PM
Alexion (ALXN) Tops Q3 Earnings, Sales Miss, Shares UpAlexion (ALXN) Tops Q3 Earnings, Sales Miss, Shares Up
finance.yahoo.com - October 26 at 3:49 PM
Celgene, Bristol-Myers Down On Poor Earnings as Big Pharma Takes It on the ChinCelgene, Bristol-Myers Down On Poor Earnings as Big Pharma Takes It on the Chin
finance.yahoo.com - October 26 at 3:49 PM
How Do Analysts See Alexion Pharmaceuticals Inc (ALXN) Performing Over The Next Year?How Do Analysts See Alexion Pharmaceuticals Inc (ALXN) Performing Over The Next Year?
finance.yahoo.com - October 26 at 3:49 PM
Alexion Pharmaceuticals, Inc. (ALXN) Announces  Earnings ResultsAlexion Pharmaceuticals, Inc. (ALXN) Announces Earnings Results
www.americanbankingnews.com - October 26 at 2:37 PM
Is A Beat In Store For Alexion This Earnings Season?Is A Beat In Store For Alexion This Earnings Season?
www.benzinga.com - October 25 at 3:33 AM
Alexion Pharma (ALXN) Announces FDA Approval of Soliris for gMGAlexion Pharma (ALXN) Announces FDA Approval of Soliris for gMG
www.streetinsider.com - October 25 at 3:33 AM
Is the Options Market Predicting a Spike in Alexion Pharmaceuticals (ALXN) Stock?Is the Options Market Predicting a Spike in Alexion Pharmaceuticals (ALXN) Stock?
finance.yahoo.com - October 25 at 3:33 AM
Alexion Pharmaceuticals Stock Jumps on FDA Approval of SolirisAlexion Pharmaceuticals Stock Jumps on FDA Approval of Soliris
finance.yahoo.com - October 25 at 3:33 AM
Alexion Pharmaceuticals, Inc. (ALXN) PT Raised to $166.00 at Royal Bank Of CanadaAlexion Pharmaceuticals, Inc. (ALXN) PT Raised to $166.00 at Royal Bank Of Canada
www.americanbankingnews.com - October 24 at 6:08 PM
Alexion Pharma (ALXN) Announces FDA Approval of Soliris for gMG - StreetInsider.comAlexion Pharma (ALXN) Announces FDA Approval of Soliris for gMG - StreetInsider.com
www.streetinsider.com - October 24 at 5:27 PM
Is the Options Market Predicting a Spike in Alexion Pharmaceuticals (ALXN) Stock? - NasdaqIs the Options Market Predicting a Spike in Alexion Pharmaceuticals (ALXN) Stock? - Nasdaq
www.nasdaq.com - October 24 at 5:27 PM
Alexion: How Do You Spell Relief?Alexion: How Do You Spell Relief?
finance.yahoo.com - October 24 at 5:27 PM

Social Media

Financials

Chart

Alexion Pharmaceuticals (NASDAQ ALXN) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.